Pharmaceuticals & Therapeutics

The expanded partnership aims to standardize care and meet soaring demand in Northwest Arkansas, integrating two new surgical facilities into the system.

With 35+ years of orthopedic sales experience, Thurman Ballard joins Tetrous to drive adoption of its groundbreaking bone-to-tendon healing technology.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

A new platform uses AI to turn complex genetic and lifestyle data into an immediate, actionable cancer prevention plan, shifting the paradigm of care.

With positive safety data for its novel UC drug, a €530M cash reserve, and a new commercial chief, Abivax is poised for a major market entry.

With a cash runway into 2027, the biotech firm prepares for critical data on its innovative bispecific antibody pipeline for hard-to-treat solid tumors.

A new collaboration aims to solve antibody reproducibility, promising to enhance diagnostic accuracy and accelerate the future of precision oncology.

The bioconjugate CRDMO reports record profits and a $1.49B backlog, fueled by tech innovation, strategic acquisitions, and global expansion.

With major expansions in the US and Europe, Cambrex aims to lead the high-stakes race for specialized API production, targeting next-generation therapies.

With a promising non-opioid drug and new leadership known for major deals, Persica Pharmaceuticals is poised to revolutionize back pain treatment.

With 17 abstracts at AAD 2026, LEO Pharma showcases real-world data to tackle treatment gaps in diverse populations and chronic skin diseases.

IntraBio's landmark FDA submission for levacetylleucine offers the first glimmer of an approved therapy for the devastating rare disease Ataxia-Telangiectasia.

A 30-year-old breakthrough could revolutionize physics and cancer detection. Its inventor now demands a public test to prove it, alleging a cover-up.

A new oral Alzheimer's drug shows potential for a lower, more patient-friendly dose, aiming to replace complex infusions with a simple daily pill.

The pharma giant is acquiring a promising 'best-in-class' PI3Kα inhibitor, SNV4818, in a move to bolster its oncology pipeline and redefine cancer care.

A new book by a top physician-scientist challenges the idea that innovation comes from the private sector, arguing Medicaid is a lab for bold experiments.

ImmunoBrain's novel immunotherapy for Alzheimer's avoids key safety issues of other drugs and shows positive biomarker data in a Phase 1b trial.

LGM Pharma is investing $15 million to expand its Texas and Colorado sites, boosting domestic production of specialized drugs and fortifying the U.S. supply chain.